Cardiovascular Inflammation Reduction Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4786 participants.
Also called NCT01594333
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,786 participants
- Registry
-
NCT01594333
-
- Other papers using this trial's data
- Adverse Effects of Low-Dose Methotrexate: A Randomized Trial
- Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial
- Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk
- Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial
- Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial
- Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate
- Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease
- Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01594333. Randomized; triple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2019-04-15 (actual). Results posted on 2020-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Inflammation Reduction Trial
- Acronym
- CIRT
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- Methotrexate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Brigham and Women's Hospital
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct01594333- Content hash
2aa8bc2ccd1f3b33f31779e5fef398613af5f213e26fbefaf07e1d5ec6862af0